(Q33895804)

29 July 2017

1 reference

title

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies (English)

1 reference

29 July 2017

1 reference

1 reference

Frank R Brennan

1

1 reference

29 July 2017

Laura Dill Morton

2

1 reference

29 July 2017

Sebastian Spindeldreher

3

1 reference

29 July 2017

Andrea Kiessling

4

1 reference

29 July 2017

Roy Allenspach

5

1 reference

29 July 2017

Adam Hey

6

1 reference

29 July 2017

Patrick Y Muller

7

1 reference

29 July 2017

Werner Frings

8

1 reference

29 July 2017

Jennifer Sims

9

1 reference

29 July 2017

publication date

23 May 2010

1 reference

29 July 2017

published in

Monoclonal Antibodies

1 reference

29 July 2017

volume

2

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

233-255

1 reference

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Immunotoxicity of monoclonal antibodies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Investigational immunotherapeutics for B-cell malignancies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Review of human DC subtypes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

The status of biologic therapies in the treatment of moderate to severe psoriasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Novel targeted therapies for autoimmunity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Anti-CD40 agonist antibodies: preclinical and clinical experience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Essentials for starting a pediatric clinical study (3): Dynamic changes in early development of immune system in macaque monkeys--the significance from standpoint of preclinical toxicity test using nonhuman primates

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Monoclonal antibodies in the therapy of multiple sclerosis: an overview

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

New approaches to prediction of immune responses to therapeutic proteins during preclinical development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Structural characterization of a human Fc fragment engineered for lack of effector functions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

NK cell tolerance and the maternal-fetal interface

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

What's so special about the developing immune system?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Testing human biologicals in animal host resistance models

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Fcgamma receptors as regulators of immune responses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

The role of the CTLA4 blockade in the treatment of malignant melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Antibody therapeutics: isotype and glycoform selection

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

FcRn: the neonatal Fc receptor comes of age.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Antigen-presenting cells and materno-fetal tolerance: an emerging role for dendritic cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Alemtuzumab in chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Immunostimulatory monoclonal antibodies for cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Influenza virus host resistance model

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Bacterial host resistance models in the evaluation of immunotoxicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

B-cell-targeted therapy for systemic lupus erythematosus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Natalizumab and progressive multifocal leucoencephalopathy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Loss of Siglec expression on T lymphocytes during human evolution

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Biologic therapies in clinical development for the treatment of rheumatoid arthritis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Tolerability and safety of rituximab (MabThera).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Siglecs in innate immunity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

The accuracy of extended histopathology to detect immunotoxic chemicals

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Species differences in the structure and function of the immune system

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Immunological relationship between the mother and the fetus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Thrombocytopenia caused by the development of antibodies to thrombopoietin

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Histopathologic approaches to detect changes indicative of immunotoxicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Differential processing of influenza nucleoprotein in human and mouse cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Peripheral blood CD4+CD8+ lymphocytes in cynomolgus monkeys are of resting memory T lineage.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Integrated studies of biology: multiplexed imaging assays from molecules to man and back

5 July 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Adverse consequences of immunostimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Progressive multifocal leukoencephalopathy after natalizumab monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Whole blood cytokine response as a measure of immunotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Development of a human adaptive immune system in cord blood cell-transplanted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Immunotoxicity evaluation by immune function tests: focus on the T-dependent antibody response (TDAR) [Overview of a Workshop Session at the 45th Annual Meeting of the Society of Toxicology (SOT) March 5-9, 2006 San Diego, CA].

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881251

Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices

29 October 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.3.11782

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

21 January 2018

1 reference

12 December 2020

Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo

1 reference

12 December 2020

Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody

1 reference

12 December 2020

Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation

1 reference

12 December 2020

STP position paper: best practice guideline for the routine pathology evaluation of the immune system

1 reference

12 December 2020

Infections Associated with Tumor Necrosis Factor-α Antagonists

1 reference

12 December 2020

IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions

1 reference

12 December 2020

Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system

1 reference

12 December 2020

"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics

1 reference

12 December 2020

1 reference

12 December 2020

Recombinant antibodies for cancer therapy

1 reference

12 December 2020

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues

1 reference

12 December 2020

Clinical immunotoxicity of therapeutic proteins

1 reference

12 December 2020

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1.

1 reference

12 December 2020

A vector driving the expression of foreign cDNAs in the MHC class II-positive cells of transgenic mice

1 reference

12 December 2020

Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice

1 reference

12 December 2020

Human leukocyte antigen-DRB1*1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice

1 reference

12 December 2020

Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research

1 reference

12 December 2020

Identifiers

DOI

10.4161/MABS.2.3.11782

1 reference

29 July 2017

1 reference

29 July 2017

1 reference